Notably, GLUT1 and GLUT3 inhibition is currently emerging as a potential strategy in the treatment of malignant disorders [35, 36], and we may thus envision that the concept of GLUT1/GLUT3 inhibition may potentially be extended to the treatment of allergic disease. The gene discussed is SLC2A1; the disease is allergic disease.